• ACADIA Pharmaceuticals CFO Mark C. Schneyer cut his stake to 67,828 shares in transactions dated Aug. 5-6.
• Sold 20,141 shares at prices around $29, including a weighted-average sale price of $29.
• Exercised options for 20,141 shares at $17.84 to cover the sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001899977-26-000008), on August 07, 2026, and is solely responsible for the information contained therein.